BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Phase 3

Completed

Conditions: Myeloid Leukemia, Chronic, Chronic-Phase

Interventions: Drug: dasatinib

First Posted Date: 2005-07-25

Last Posted Date: 2016-08-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 724

Registration Number: NCT00123474

Locations: 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 38 locations

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Phase 3

Completed

Conditions: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Myeloid Leukemia, Chronic, Accelerated Phase

Interventions: Drug: dasatinib

First Posted Date: 2005-07-25

Last Posted Date: 2014-11-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 638

Registration Number: NCT00123487

Locations: 🇺🇸
The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸
Emory University School Of Medicine, Atlanta, Georgia, United States

and more 24 locations

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: placebo
Drug: methotrexate

First Posted Date: 2005-07-22

Last Posted Date: 2010-11-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1052

Registration Number: NCT00122382

Locations: 🇬🇧
Local Institution, Newcastle, Northumberland, United Kingdom
🇺🇸
Lion Research, Norman, Oklahoma, United States
🇺🇸
Diagnostic Rheumatology And Research, Indianapolis, Indiana, United States

and more 17 locations

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group)

First Posted Date: 2005-07-18

Last Posted Date: 2010-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 192

Registration Number: NCT00120393

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Abatacept
Drug: Prednisone

First Posted Date: 2005-07-14

Last Posted Date: 2014-09-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 183

Registration Number: NCT00119678

Locations: 🇺🇸
8737 Beverly Blvd., Los Angeles, California, United States
🇺🇸
Office Of Geoffrey S. Dolan, Md, Long Beach, California, United States
🇺🇸
Kentuckiana Center For Better Bone And Joint Health, Louisville, Kentucky, United States

and more 10 locations

DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Not Applicable

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-30

Last Posted Date: 2011-04-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 65

Registration Number: NCT00116415

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States

Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)

Phase 3

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-29

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 900

Registration Number: NCT00116298

Locations: 🇹🇭
Local Institution, Nontaburi, Thailand

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Phase 4

Completed

Conditions: HIV Infections
AIDS

First Posted Date: 2005-06-28

Last Posted Date: 2011-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT00116116

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporin A
Drug: Belatacept More Intensive Regimen (MI)
Drug: Belatacept Less Intensive Regimen (LI)

First Posted Date: 2005-06-20

Last Posted Date: 2017-07-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 595

Registration Number: NCT00114777

Locations: 🇺🇸
Sharp Memorial Hospital, San Diego, California, United States
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
National Institute Of Transplantation, Los Angeles, California, United States

and more 26 locations

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Not Applicable

Completed

Conditions: Sepsis
Nosocomial Infections
Staphylococcal Infections
Candidemia

First Posted Date: 2005-06-07

Last Posted Date: 2012-08-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2000

Registration Number: NCT00113191

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy